APC
RDHL

Aspire Private Capital’s Redhill Biopharma RDHL Stock Holding History

Aspire Private Capital’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16
Closed -$215 – 736
2024
Q1 		$215 Hold
16
– – ﹤0.01% 685
2023
Q4 		$592 Buy
+16
New +$326 ﹤0.01% 634

Other funds holding RDHL

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $6.06B AUM 28.9% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Aspire Private Capital's RDHL Position: Q2 2024 in Review

Aspire Private Capital sold out of Redhill Biopharma (RDHL) in Q2 2024, closing a stake of 16 shares — an estimated $215 sold.

Aspire Private Capital first reported a position in RDHL in Q4 2023 and held it in 2 quarters. The position peaked at $592 in Q4 2023. 16 funds tracked by Wall St. Rank hold RDHL as of Q2 2024.

  • Aspire Private Capital reported no remaining Redhill Biopharma position as of Q2 2024 after selling out during the quarter.
  • Aspire Private Capital sold 16 Redhill Biopharma shares in Q2 2024, an estimated $215.
  • Aspire Private Capital first reported a position in Redhill Biopharma in Q4 2023 and held it in 2 quarters.
  • Aspire Private Capital's Redhill Biopharma position peaked at $592 in Q4 2023.
  • 16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2024.

Based on Aspire Private Capital's 13F filing for Q2 2024, filed 15 Jul 2024.